Myriad Genetics (MYGN) Return on Invested Capital (2016 - 2026)

Myriad Genetics (MYGN) has reported Return on Invested Capital for 9 consecutive years, with 0.07% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Invested Capital changed N/A year-over-year to 0.07%; the TTM figure through Mar 2026 stood at 0.07% (changed N/A YoY), while the FY2020 annual figure was 0.64%, changed N/A from the prior year.
• Return on Invested Capital declined to 0.07% in Q1 2026 per MYGN's latest filing, from 0.06% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.0% in Q1 2022 and bottomed at 0.07% in Q3 2025.
• Historically, Return on Invested Capital has averaged 0.05% across 3 years, with a median of 0.06% in 2025.
• On a YoY basis, Return on Invested Capital climbed as much as 57 bps in 2022 and fell as far as 57 bps in 2022.
• Myriad Genetics' Return on Invested Capital stood at 0.0% in 2022, then tumbled by 1434 bps to 0.06% in 2025, then dropped by 8 bps to 0.07% in 2026.
• Business Quant data shows MYGN's Return on Invested Capital at 0.07% in Q1 2026, 0.06% in Q4 2025, and 0.07% in Q3 2025.